Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of beta-catenin as a biomarker for treating cancers using anti-Dkk-1 antibody

Use of beta-catenin as a biomarker for treating cancers using anti-Dkk-1 antibody

US Patent 12319730 · Granted Jun 3, 2025

Assignee

No assignee recorded.

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibod2022
Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibod2022
Treatment of conditions associated with hyperinsulinaemia2021
Bromodomain inhibitors2018